11.06.2015 • NewsDede WillamsAstraZenecaAmgen

AstraZeneca Weighs Continuation of Psoriasis Drug

AstraZeneca is mulling whether to independently pursue the developmental psoriasis drug brodalumab after its partner Amgen’s withdrawal from the project in May, Pascal Soriot, chief executive officer of the UK drugmaker, told the news agency Bloomberg.
Amgen terminated the development deal after patients showed suicidal tendencies.
Soriot said AstraZeneca, which began its collaboration with Amgen three years ago, wants to take more time to look at the data and engage with regulators.
The UK company initially paid the biotech firm $50 million and agreed to fund 65% of the cost of the developing of five new drugs from 2012 to 2014. After that, the partners planned to split costs and profits.
Even with the potential loss of brodalumab, expected to have peak sales of $1.5 billion, AstraZeneca can still reach its target of $45 billion in annual sales by 2023, Soriot told the news agency.
The drug treats the skin disease and related forms of arthritis.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.